Year end reflections

As we approach the end of the year, I want to share my gratitude and optimism, even in the context of how depressing Parkinson's can be.

First, we've made so much progress at Right Brain Bio, albeit mostly behind the scenes. Review of the data continues to withstand scientific scrutiny. Yes there are skeptics and nay-sayers, but those who spend the time to review the data typically agree that this development program is worthwhile. Manufacturing of the drug should start by the end of this year or early next. Clinical sites have been identified. We've received encouragement to submit grant applications from groups that seemed uninterested just a year or two ago.

Second, I've heard from many of you about your situations in ways that keep me focused and inspired. I can't respond to all the messages I receive, but I read them all and respond as much as possible. I apologize but responding can't be my first priority as it can be a distraction from doing the work to launch the first trial ASAP. And it means so much when people tell me that they want to volunteer for the trials (note that when the final trial protocol is approved, I will post in this newsletter the criteria for participation).

After this newsletter, I do not plan to send out any more until after January 1st. But that doesn't mean I am going on vacation. We have a ton of work to do including writing two grant applications to expedite launch of clinical trials.

Wishing you a Happy Thanksgiving, happy and healthy New Year's and wonderful holiday season.


Share This

About Jonathan Sackner-Bernstein, MD

Dr. Sackner-Bernstein shares his pursuit of conquering Parkinson's, using expertise developed as Columbia University faculty, FDA senior official, DARPA insider and witness to the toll of PD.
Dr. S-B’s Linkedin page

RightBrainBio, Inc. was incorporated in 2022 to develop tranformative therapies for people with Parkinson's.